title: [Vortioxetine: a new antidepressant to treat depressive episodes].
abstract: Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Its efficacy and safety were assessed in fourteen studies including more than 3700 patients with a major depressive episode and treated with vortioxetine. In short-term studies (8 weeks), vortioxetine is more efficacious than placebo in decreasing depressive symptoms as measured by the MADRS total score, response rate (vortioxetine: 53.2% vs placebo: 35.2%) and remission rate (vortioxetine: 29.2% vs placebo: 19.3%). In a long-term study (52 weeks), vortioxetine is also superior to placebo in preventing relapses and recurrences. Moreover, in second line treatment, after failure of a first line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrin reuptake inhibitor (SNRI), vortioxetine is superior to agomelatine in improving depressive symptoms and achieving response and remission. Furthermore, the positive effects of vortioxetine on improvement of cognitive symptoms of major depressive episodes are particularly well established in several clinical trials. The tolerability profile of vortioxetine is favourable. The recommended daily posology of vortioxetine is 10mg/d. Vortioxetine is a new antidepressant drug with a multimodal mechanism of action, well-documented efficacy and safety profiles.
authors.affiliation: Faculté de médecine Paris Sud, Inserm U 1178 santé mentale et santé publique, équipe « Dépression et Antidépresseurs », CHU de Bicêtre, AP-HP, 94276 Le Kremlin-Bicêtre, France; Service de psychiatrie, CHU de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France.
authors.forename: R
authors.initials: R
authors.lastname: Colle
authors.affiliation: Faculté de médecine Paris Sud, Inserm U 1178 santé mentale et santé publique, équipe « Dépression et Antidépresseurs », CHU de Bicêtre, AP-HP, 94276 Le Kremlin-Bicêtre, France; Service de psychiatrie, CHU de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France. Electronic address: emmanuelle.corruble@bct.aphp.fr.
authors.forename: E
authors.initials: E
authors.lastname: Corruble
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D018490:Serotonin Agents / Q000494:pharmacology / Q000627:therapeutic use; D013440:Sulfides / Q000494:pharmacology / Q000627:therapeutic use*; D000078784:Vortioxetine
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D018490:Serotonin Agents; D013440:Sulfides; D000078784:Vortioxetine
keywords: Antidepressant; Antidépresseur; Depression; Dépression; Efficacité; Efficacy; Major depressive disorder; Major depressive episode; Psychopharmacologie; Psychopharmacology; Safety; Therapeutics; Thérapeutique; Tolérance; Trouble dépressif caractérisé; Vortioxetine; Vortioxétine; Épisode dépressif caractérisé